

2017/**In press**

1. Mizushima J, Uchida H, Tada M, Suzuki T, Mimura M, Nio S. Early improvement of specific symptoms predicts subsequent treatment recovery in bipolar depression: reanalysis of the systematic treatment enhancement program for bipolar disorder (STEP-BD) data. *J Clin Psychiatry* (in press)
2. Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate versus gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. *Schizophr Bull* (in press)
3. Reeves S, Bertrand J, McLachlan E, D'Antonio F, Brownings S, Nair A, Greaves S, Smith A, Dunn J, Marsden P, Kessler R, Uchida H, Taylor D, Howard R. A population approach to guide amisulpride dose adjustments in older patients with Alzheimer's disease. *J Clin Psychiatry* (in press)
4. Yoshida K, Roberts R, Suzuki T, Lebowitz B, Reeves S, Howard R, Abe T, Mimura M, Uchida H. Lack of early improvement with antipsychotics is a marker for subsequent non-response in behavioral and psychological symptoms of dementia: Analysis of CATIE-AD data. *Am J Geriatr Psychiatry* (in press)
5. Gerretsen P, Takeuchi H, Ozzoude M, Graff-Guerrero A, Uchida H. Insight into illness and its relationship to illness severity, cognition and estimated antipsychotic dopamine receptor occupancy in schizophrenia: an antipsychotic dose reduction study. *Psychiatry Res* (in press)
6. Hirano J, Takamiya A, Yamagata B, Hotta S, Miyasaka Y, Pu S, Iwanami A, Uchida H, Mimura M. Frontal and temporal cortical functional recovery after electroconvulsive therapy for depression: A longitudinal functional near-infrared spectroscopy study. *J Psychiatr Res* (in press)
7. Goff DC, Falkai P, Fleischhacker WW, Girgis RR, Kahn RM, Uchida H, Zhao J, Lieberman JA. The long-term effects of antipsychotic medication on clinical course in schizophrenia. *Am J Psychiatry* (in press)
8. Ozawa C, Roberts R, Yoshida K, Suzuki T, Lebowitz B, Reeves S, Robert H, Abe T, Mimura M, Uchida H. Placebo effects in the treatment of non-cognitive symptoms of Alzheimer's disease: analysis of the CATIE-AD data. *J Clin Psychiatry* (in press)
9. Ayaki M, Kawashima M, Negishi K, Kishimoto T, Mimura M, Tsubota K. Sleep and mood disorders in women with dry eye disease. *Sci Rep* (in press)
10. Caravaggio F, Nakajima S, Plitman E, Gerretsen P, Chung J, Iwata Y, Graff-Guerrero A. The effect of striatal dopamine depletion on striatal and cortical glutamate: a mini-review. *Prog Neuropsychopharmacol Biol Psychiatry*. (in press)

11. Yoshimura M, Kitazawa M, Maeda Y, Mimura M, Tsubota K, Kishimoto T. Smartphone Viewing Distance and Sleep: An Experimental Study Utilizing Motion Capture Technology. *Nat Sci Sleep* (in press)
12. Yu-Tao Xiang, Kishimoto T. Comparison of treatment patterns in schizophrenia between China and Japan (2001-2009). *Asia Pac Psychiatry* (in press)
13. Nakagawa A, Sado M, Mitsuda D, Fujisawa D, Kikuchi T, Abe T, Sato Y, Iwashita S, Mimura M, Ono Y. Effectiveness of Supplementary Cognitive Behavioral Therapy for Pharmacotherapy-resistant Depression: A Randomized Controlled Trial. *J Clin Psychiatry* (in press)
14. Fervaha G, Takeuchi H, Foussias G, Hahn MK, Agid O, Remington G. Achievement motivation in early schizophrenia: relationship with symptoms, cognition and functional outcome. *Early Interv Psychiatry* (in press)
15. Harber L, Takeuchi H, Borlido C, Hamidian R, Remington G. Factors associated with drug attitude in patients with schizophrenia spectrum disorders. *Schizophr Res* (in press)
16. Takeuchi H, Thiyanavadivel S, Agid O, Remington G. Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. *Schizophr Res* (in press)
17. Takeuchi H, Kantor N, Sanches M, Fervaha G, Agid O, Remington G. One-Year Symptom Trajectories in Patients with Stable Schizophrenia Maintained on Antipsychotics vs. Placebo: A Meta-analysis. *Br J Psychiatry* (in press)
18. Nagata T, Nakajima S, Shinagawa S, Plitman E, Graff-Guerrero A, Mimura M, Nakayama K. Psychosocial or Clinico-Demographic Factors Related to Neuropsychiatric Symptoms in Patients with Alzheimer's Disease Needing Interventional Treatment - Analysis of the CATIE-AD Study. *Int J Geriatr Psychiatry* (in press)
19. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JT, Kane J, Correll CU. Treatment resistant schizophrenia: Treatment Response and Resistance in

- Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. *Am J Psychiatry* (in press)
20. Le Foll B, Payer D, Thiruchselvam T, Lu SX, Mohammed S, Mansouri E, Lagzdins D, Nakajima S, Wilson A, Graff-Guerrero A, Di Ciano P, Boileau I. Investigating the effects of norepinephrine α 1 receptor blockade on dopamine levels: A pilot PET study with [11C]-(+)-PHNO in controls. *Synapse* (in press)
 21. Gerretsen P, Chung J, Parita S, Plitman E, Iwata Y, Nakajima S, Graff-Guerrero A. Impaired Illness Awareness as a Predictor of Conversion from MCI to AD and a Function of Reduced Brain Metabolism: An ADNI study. *J Clin Psychiatry* (in press)
 22. Chung J, Plitman E, Nakajima S, Chakravarty M, Caravaggio F, Takeuchi H, Gerretsen P, Iwata Y, Patel R, Mulsant B, Graff-Guerrero A. Hippocampal and clinical trajectories of mild cognitive impairment with suspected non-Alzheimer's pathology. *J Alzheimers Dis.* (in press)
 23. Plitman E, Iwata Y, Carravaggio F, Nakajima S, Chung J, Gerretsen P, Kim J, Takeuchi H, Chakravarty M, Remington G, Graff-Guerrero A. Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. *Schizophr Bull* (in press)
 24. Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: A systematic review and meta-analysis. *JAMA Psychiatry* (in press)
 25. Caravaggio F, Chung J, Gerretsen P, Fervaha G, Nakajima S, Plitman E, Iwata Y, Wilson A, Graff-Guerrero A. Exploring the relationship between social attachment and dopamine D2/3 receptor availability in the brains of healthy humans using [11C]-(+)-PHNO. *Social Neuroscience.* 2017; 12: 163-173.
 26. Taishiro Kishimoto, MD, Sohag Sanghani, Mark J Russ, Akeem N Marsh, Joshua Morris, Suparna Basu, Majnu John, John M Kane. Indications for and Use of Long Acting Injectable Antipsychotics: Consideration from an Inpatient Setting. *Int Clin Psychopharmacol.* 2017; 32: 161-8.
 27. Payer D, Williams B, Mansouri E, Stevanovski S, Nakajima S, Le Foll B, Kish S, Houle S, Mizrahi R, George S, George TP, Boileau I. Corticotropin-Releasing Hormone and Dopamine Release in Healthy Individuals. *Psychoneuroendocrinology.* 2017; 76: 192-196.
 28. Kim J, Plitman E, Nakajima S, Chung J, Alshehri Y, Iwata Y, Caravaggio F, Pollock BG, Pothier D, Graff-Guerrero A, Gerretsen P. Impaired Illness Awareness and Leftward Visuospatial Inattention in Schizophrenia Are Attributable to a Common

Neural Deficit – Posterior Parietal Hemispheric Imbalance. *Med Hypotheses*. 2017; 100: 19-22.

29. Takeuchi H, Lee J, Fervaha G, Foussias G, Agid O, Remington G. Switching to clozapine using immediate vs. gradual antipsychotic discontinuation: a pilot, double-blind, randomized controlled trial. *J Clin Psychiatry*. 2017; 78: 223-8.
30. Takeuchi H, Thiyanavadivel S, Fervaha G, Remington G. Neurocognitive benefits of second-generation antipsychotics vs. placebo: Insufficient evidence based on a systematic review. *J Clin Psychopharmacol*. 2017; 37: 274-6.
31. Tsutsui-Kimura I, Takiue H, Yoshida K, Xu M, Yano R, Ohta H, Nishida H, Bouchekioua Y, Okano H, Uchigashima M, Watanabe M, Takata N, Drew MR, Sano H, Mimura M, Tanaka KF. Dysfunction of ventrolateral striatal dopamine receptor type 2-expressing medium spiny neurons impairs instrumental motivation. *Nat Commun*. 2017; 8: 14304.

2016

1. Ikai S, Suzuki T, Uchida H, Saito H, Mimura M, Takeuchi H. Prescription patterns for depression among consultation-liaison psychiatrists and non-psychiatrists: a chart-review. *Int J Geriatr Psychiatry*. 2016; 31: 1084-5.
2. Funaki K, Nakajima S, Suzuki T, Mimura M, Uchida H. Early improvements in individual symptoms to predict later remission in major depressive disorder treated with mirtazapine. *J Clin Pharmacology*. 2016; 56: 1111-9.
3. Sakurai H, Suzuki T, Bies RR, Pollock BG, Mimura M, Kapur S, Uchida H. Increasing versus maintaining the dose of olanzapine or risperidone for schizophrenia patients who did not respond to modest dosage: a double-blind randomized controlled trial. *J Clin Psychiatry*. 2016; 77: 1381-1390.
4. Iwata Y, Nakajima S, Uchida H, Plitman E, Chung JK, Mar WM, Gerretsen PPollock BG, Mulsant BH, Rajji TK, Mamo DC, Graff-Guerrero A. Threshold of dopamine D_{2/3} receptor occupancy for hyperproactinemia in older patients with schizophrenia. *J Clin Psychiatry*. 2016; 77: e1557-e1563.
5. Lee J, Bies R, Takeuchi H, Fervaha G, Bhaloo A, Powell V, Remington G. Quantifying intraindividual variations in plasma clozapine levels: A population pharmacokinetic approach. *Journal of Clinical Psychiatry*. 2016; 77: 681-7.
6. Fervaha G, Agid O, Foussias G, Siddiqui I, Takeuchi H, Remington G. Neurocognitive impairment in the deficit subtype of schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience*. 2016; 266: 397-407.

7. Le Foll B, Payer D, Di Ciano P, Guranda M, Nakajima S, Tong J, Mansouri E, Wilson A, Houle S, Meyer J, Graff-Guerrero A, Boileau I. Occupancy of Dopamine D3 and D2 Receptors by Bupirone: A [¹¹C]-(+)-PHNO PET Study in Humans. *Neuropsychopharmacology*. 2016; 41: 529-37.
8. Chung J, Plitman E, Nakajima S, Chakravarty M, Caravaggio F, Gerretsen P, Iwata Y, Graff-Guerrero A, for the Alzheimer's Disease Neuroimaging Initiative. Cortical beta-amyloid deposition and current depressive symptoms in Alzheimer's disease and mild cognitive impairment. *J Geriatr Psychiatry Neurol*. 2016; 29: 149-59.
9. Chung J, Plitman E, Nakajima S, Chakravarty M, Caravaggio F, Takeuchi H, Gerretsen P, Iwata Y, Patel R, Mulsant B, Graff-Guerrero A, for the Alzheimer's Disease Neuroimaging Initiative. Depressive symptoms and small hippocampal volume accelerate the progression to dementia from mild cognitive impairment. *J Alzheimers Dis*. 2016; 49: 743-54.
10. Nagata T, Shinagawa S, Nakajima S, Plitman E, Mihashi Y, Hayashi S, Mimura M, Nakayama K. Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer Disease – analysis of CATIE-AD study. *J Alzheimers Dis*. 2016; 50: 839-45.
11. Caravaggio F, Borlido C, Fervaha G, Gerretsen P, Nakajima S, Plitman E, Chung J, Iwata Y, Wilson A, Remington G, Graff-Guerrero A. Exploring personality traits related to dopamine D2/3 receptor availability in striatal subregions of humans. *Eur Neuropsychopharmacology*. 2016; 26: 644-52.
12. Nakajima S, Uchida H, Bies RR, Caravaggio F, Suzuki T, Plitman E, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Mamo DC, Graff-Guerrero A. Dopamine D2/3 receptor occupancy following dose reduction is predictable with minimal plasma antipsychotic concentrations: an open-label clinical trial. *Schizophr Bull*. 2016; 42: 212-9.
13. Kitahata R, Nakajima S, Suzuki T, Plitman E, Mimura M, Uchida H. Relapse of ileus in patients with psychiatric disorders: a 2-year chart review. *Gen Hosp Psychiatry*. 2016; 38: 31-6.
14. Ikai S, Uchida H, Suzuki T, Tsunoda K, Fujii Y, Mimura M. Postural sway and flexibility in patients with schizophrenia-spectrum disorders: a cross-sectional study. *Asian Journal of Psychiatry*. 2016; 19: 14-8.
15. Yoshida K, Suzuki T, Imasaka Y, Kubo K, Mizuno Y, Saruta J, Tsukinoki K, Mimura M, Uchida H. Resilience in schizophrenia: a comparative study between a remote island and an urban area in Japan. *Schizophr Res*. 2016; 171: 92-6.

16. Hofer A, Mizuno Y, Frajo-Apor B, Kemmler G, Suzuki T, Pardeller S, Rauch AS, Sondermann C, Mimura M, Wartelsteiner F, Fleischhacker WW, Uchida H. Resilience, internalized stigma, self-esteem, and hopelessness among people with schizophrenia: cultural comparison in Austria and Japan. *Schizophr Res.* 2016; 171: 86-91.
 17. Suzuki T. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal. *Expert Opin Drug Deliv.* 2016; 13: 253-64.
 18. Fervaha G, Foussias G, Takeuchi H, Agid O, Remington G. Motivational deficits in major depressive disorder: cross-sectional and longitudinal relationships with functional impairment and subjective well-being. *Comprehensive Psychiatry.* 2016; 66: 31-8.
 19. Mizuno Y, Wartelsteiner F, Frajo-Apor B. Resilience research in schizophrenia: a review of recent developments. *Curr Opin Psychiatry.* 2016; 29: 218-223.
 20. Yoshida K, Suzuki T, Imasaka Y, Kubo K, Mizuno Y, Saruta J, Tsukinoki K, Mimura M, Uchida H. Resilience in schizophrenia: a comparative study between a remote island and an urban area in Japan. *Schizophr Res* 171: 92-6; 2016
 21. Hofer A, Mizuno Y, Frajo-Apor B, Kemmler G, Suzuki T, Pardeller S, Rauch AS, Sondermann C, Mimura M, Wartelsteiner F, Fleischhacker WW, Uchida H. Resilience, internalized stigma, self-esteem, and hopelessness among people with schizophrenia: cultural comparison in Austria and Japan. *Schizophr Res* 171: 86-91; 2016
 22. Mizuno Y, Hofer A, Suzuki T, Frajo-Apor B, Wartelsteiner, Kemmler G, Saruta J, Tsukinoki K, Mimura M, Fleischhacker WW, Uchida H. Clinical and biological correlates of resilience in patients with schizophrenia and bipolar disorder: a cross-sectional study. *Schizophr Res* 175: 148-153; 2016
 23. Ikai S, Suzuki T, Uchida H, Saito H, Mimura M, Takeuchi H. Prescription patterns for depression among consultation-liaison psychiatrists and non-psychiatrists: a chart-review. *Int J Geriatr Psychiatry* 31: 1084-5; 2016
 24. **Sakurai H, Suzuki T, Bies RR, Pollock BG, Mimura M, Kapur S, Uchida H. Increasing versus maintaining the dose of olanzapine or risperidone for schizophrenia patients who did not respond to modest dosage: a double-blind randomized controlled trial. *J Clin Psychiatry* 77: 1381-90; 2016
- ** This paper was awarded the Paul Janssen Award by the Japanese Society of Clinical Neuropsychopharmacology (November 2016).

25. Funaki K, Nakajima S, Suzuki T, Mimura M, Uchida H. Early improvements in individual symptoms to predict later remission in major depressive disorder treated with mirtazapine. *J Clin Pharmacology* 56: 1111-9; 2016
26. Iwata Y, Nakajima S, Uchida H, Plitman E, Chung JK, Mar WM, Gerretsen P, Pollock BG, Mulsant BH, Rajji TK, Mamo DC, Graff-Guerrero A. Threshold of dopamine D_{2/3} receptor occupancy for hyperprolactinemia in older patients with schizophrenia. *J Clin Psychiatry* 77: 1557-63; 2016
27. Ishida T, Sakurai H, Watanabe K, Iwashita S, Mimura M, Uchida H. Incidence of deep vein thrombosis in catatonic patients: a chart review. *Psychiatr Res* 241: 61-5; 2016
28. Fujii K, Suzuki T, Mimura M, Uchida H. Psychological dependence on antidepressants in patients with panic disorder: a cross-sectional study. *Int Clin Psychopharmacol* 32: 36-40; 2016
29. Wartelsteiner F, Mizuno Y, Frajo-Apor B, Kemmler G, Pardeller S, Sondermann C, Welte AS, Fleischhacker WW, Uchida H, Hofer A. Quality of life in stabilized schizophrenia patients is mainly associated with resilience and self-esteem. *Acta Psychiatr Scand* 134: 360-7; 2016
30. Ikai S, Suzuki T, Mimura M, Uchida H. Estimated dopamine D₂ receptor occupancy with risperidone long-acting injectable during maintenance treatment of schizophrenia: a 3-year follow-up study. *Psychopharmacology* 233: 4003-10; 2016
31. Ayaki M, Kawashima M, Negishi K, Kishimoto T, Mimura M, Tsubota K. Sleep and mood disorders in dry eye disease and allied irritating ocular diseases. *Sci Rep*. 2016; 1; 6: 22480.
32. Takaesu Y, Kishimoto T, Murakoshi A, Takahashi N, Inoue Y. Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: A prospective observational study. *Psychiatr Res*. 2016; 236: 71-4.
33. Nielsen J, Young C, Ifteni P, Kishimoto T, Xian YT, Schukte PF, Correll CU, Taylor D. Worldwide differences in regulations of clozapine use. *CNS Drugs*. 2016; 30: 149-61.
34. Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU. Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. *Psychol Med*. 2016; 12: 1-14.

35. Yoshimura M, Kitazawa M, Kishimoto T, Mimura M, Tsubota K. A Survey of Japanese young adult's postures when using smartphones before sleeping. *Journal MTM*. 2016; 2: 51-53.
36. Misawa F, Hagi K, Kishimoto T, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. *Schizophr Res*. 2016; 176: 220-30
37. Lo Cascio N, Saba R, Hauser M, Vernal DL, Al-Jadiri A, Borenstein Y, Sheridan EM, Kishimoto T, Armando M, Vicari S, Fiori Nastro P, Girardi P, Gebhardt E, Kane JM, Auther A, Carrión RE, Cornblatt BA, Schimmelmann BG, Schultze-Lutter F, Correll CU. Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. *Eur Child Adolesc Psychiatry*. 2016; 25: 1091-102.
38. Watanabe K, Harada E, Inoue T, Tanji Y, Kikuchi T. Perceptions and impact of bipolar disorder in Japan: results of an Internet survey. *Neuropsychiatr Dis Treat*. 2016; 12: 2981-2987.
39. Ayani N, Sakuma M, Morimoto T, Kikuchi T, Watanabe K, Narumoto J, Fukui K. The epidemiology of adverse drug events and medication errors among psychiatric inpatients in Japan: the JADE study. *BMC Psychiatry*. 2016; 16: 303.
40. Harada E, Sato Y, Kikuchi T, Watanabe K, Alev L, Mimura M. Residual symptoms in patients with partial versus complete remission of a major depressive disorder episode: patterns of painful physical symptoms in depression. *Neuropsychiatr Dis Treat*. 2016; 12: 1599-607.
41. Schneck N, Miller JM, Delorenzo C, Kikuchi T, Sublette ME, Oquendo MA, Mann JJ, Parsey RV. Relationship of the serotonin transporter gene promoter polymorphism (5-HTTLPR) genotype and serotonin transporter binding to neural processing of negative emotional stimuli. *J Affect Disord*. 2016; 190: 494-8.
42. Chung J, Nakajima S, Plitman E, Caravaggio F, Gerretsen P, Iwata Y, Uy D, Chakravarty M, Graff-Guerrero A. Beta-amyloid burden is not associated with cognitive impairment in schizophrenia: A systematic review. *Am J Geriatr Psychiatry*. 2016; 24: 923-39.
43. Chung J, Nakajima S, Shinagawa S, Plitman E, Iwata Y, Carravaggio F, Chakravarty M, Gerretsen P, Graff-Guerrero A. Benzodiazepine use reduces cortical beta-amyloid levels and is not associated with progressive cognitive decline

- in non-demented elderly adults: A pilot study using F18 -Florbetapir Positron Emission Tomography. *Am J Geriatr Psychiatry*. 2016; 24: 1028-1039.
44. Fervaha G, Caravaggio F, Mamo D, Mulsant B, Pollock B, Nakajima S, Gerretsen P, Rajji T, Mar W, Iwata Y, Plitman E, Chung J, Remington G, Graff-Guerrero A. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. *Psychopharmacology (Berl)*. 2016 Oct;233(21-22):3803-3813.
 45. Takeuchi H, Fervaha G, Remington G. Consistency between clinician and patient ratings of clozapine-induced side effects. *Schizophrenia Research*. 2016; 174: 200-1.
 46. Takeuchi H, Powell V, Geisler S, DeSanti M, Fervaha G, Agid O, Kane JM, Remington G. Clozapine administration in clinical practice: once-daily versus divided dosing. *Acta Psychiatrica Scandinavica*. 2016; 134: 234–40.
 47. Remington G, Lee J, Agid O, Takeuchi H, Foussias G, Hahn M, Fervaha G, Burton L, Powell V. Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use. *Expert Opin Drug Saf*. 2016; 15: 1193-203.
 48. Takeuchi H, Fervaha G, Lee J, Remington G. What symptom domains are associated with patient distress in schizophrenia? *Schizophr Res*. 2016; 176: 329-30.
 49. Fervaha G, Takeuchi H, Foussias G, Agid O, Remington G. Using poverty of speech as a case study to explore the overlap between negative symptoms and cognitive dysfunction. *Schizophr Res*. 2016; 176: 411-6.
 50. Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Life satisfaction and happiness among young adults with schizophrenia. *Psychiatry Res*. 2016; 242: 174-9.
 51. Takeuchi H, Fervaha G, Lee J, Agid O, Remington G. A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD). *J Psychiatric Res*. 2016; 80: 87-92.
 52. Takeuchi H, Fervaha G, Remington G. Reliability of a patient-reported outcome measure in schizophrenia: results from back-to-back self-ratings. *Psychiatry Res*. 2016; 244: 415–9.
 53. Takeuchi H, Fervaha G, Remington G. Incidence of antipsychotic-associated side effects: impact of clinician vs. patient ratings and absolute vs. change scores. *J Clin Psychopharmacol*. 2016; 36: 593-6.

54. Remington G, Foussias G, Fervaha G, Agid O, Takeuchi H, Lee J, Hahn M. Treating Negative Symptoms in Schizophrenia: an Update. *Curr Treat Options Psychiatry*. 2016; 3:133-50.

2015

1. Ueno F, Nakajima S, Suzuki T, Abe T, Sato Y, Mimura M, Uchida H. Whether to increase or maintain dosage of mirtazapine in early non-improvers with depression. *J Clin Psychiatry*. 2015; 76: 434-9.
2. Ohtani A, Suzuki T, Takeuchi H, Uchida H. Language barrier and access to psychiatric care: a systematic review. *Psychiatr Serv*. 2015; 66: 798-805.
3. Suzuki T, Uchida H, Sakurai H, Ishizuki T, Tsunoda K, Takeuchi H, Mimura M. Relationships between Global Assessment of Functioning and other rating scales in clinical trials for schizophrenia. *Psychiatry Res*. 2015; 30: 265-9.
4. Hayashi K, Uchida H, Takaoka C, Izawa Y, Shinoda M, Obara H, Itano O, Shirahase J, Tanabe M, Kitagawa Y, Mimura M. Discrepancy in psychological attitudes towards living donor liver transplantation between recipients and donors. *Transplantation*. 2015; 99: 2551-5.
5. Tsuboi T, Suzuki T, Bies RR, Remington G, Pollock BG, Mimura M, Uchida H. Challenging the need for sustained blockade of dopamine D2 Receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: a single-blind, randomized, controlled study. *Schizophr Res*. 2015; 164: 149-54.
6. Suzuki T, Uchida H, Takeuchi H, Tsunoda K, Ishizuki T, Mimura M. Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year. *Psychiatry Res*. 2015; 228: 26-30.
7. Tada M, Uchida H, Maeda T, Konishi M, Umeda S, Terasawa Y, Nakajima S, Mimura M, Miyazaki T, Takahashi T. Fear conditioning induced by interpersonal conflicts in healthy individuals. *PLOS ONE*. 2015; 10: e0125729.
8. Ikai S, Suzuki T, Uchida H, Saito H, Mimura M, Takeuchi H. A questionnaire survey of Japanese non-psychiatrists' attitudes on management of depression in a general hospital. *Asian J Psychiatry*. 2015; 15: 73-4.
9. Takeuchi H, Fervaha G, Lee J, Agid O, Remington G. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. *European Neuropsychopharmacology*. 2015; 25: 295-302.
10. Fervaha G, Takeuchi H, Agid O, Lee J, Foussias G, Remington G. Determinants of patient-rated and clinician-rated illness severity in schizophrenia. *Journal of Clinical Psychiatry*. 2015; 76: 924-30.

11. Fervaha G, Takeuchi H, Lee J, Foussias G, Fletcher PJ, Agid O, Remington G. Antipsychotics and amotivation. *Neuropsychopharmacology*. 2015; 40: 1539-48.
12. Lee J, Takeuchi H, Fervaha G, Sin GL, Foussias G, Agid O, Farooq S, Remington G. Subtyping schizophrenia by treatment response: antipsychotic development and the central role of positive symptoms. *Can J Psychiatry*. 2015; 60: 515-22.
13. Lee J, Fervaha G, Takeuchi H, Powell V, Remington G. Positive symptoms as key determinants of clinicians' global impression in treatment-resistant schizophrenia. *J Clin Psychopharmacol*. 2015; 35: 237-41.
14. Shinagawa S, Nakajima S, Plitman E, Graff-Guerrero A, Mimura M, Nakayama K, Miller B. Non-pharmacological management for patients with frontotemporal dementia. *J Alzheimers Dis*. 2015; 45: 283-93.
15. Nakajima S, Takeuchi H, Fervaha G, Plitman E, Gerretsen P, Chung J, Caravaggio F, Iwata Y, Mihashi Y, Remington G, Mulsant B, Graff-Guerrero A. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE Phase 2E data. *Schizophr Res*. 2015; 161: 429-33.
16. Chung J, Plitman E, Nakajima S, Chow T, Chakravarty M, Carravaggio F, Gerretsen P, Brown E, Iwata Y, Graff-Guerrero A, for the Alzheimer's Disease Neuroimaging Initiative. Cortical beta-amyloid deposition and life-time depressive symptoms in Alzheimer's disease and mild cognitive impairment. *J Alzheimers Dis*.
17. Nakajima S, Takeuchi H, Plitman E, Fervaha G, Gerretsen P, Chung J, Caravaggio F, Iwata Y, Remington G, Graff-Guerrero A. Neuroimaging findings in treatment resistant schizophrenia: a systematic review. *Schizophr Res*. 2015; 45: 907-19.
18. Caravaggio F, Borlido C, Hahn M, Feng Z, Fervaha G, Gerretsen P, Nakajima S, Plitman E, Chung JK, Iwata Y, Wilson A, Remington G, Graff-Guerrero A. Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy non-obese humans. *International Journal of Neuropsychopharmacology*. 2015; 18: pyv014.
19. Nakajima S, Caravaggio F, Gerretsen P, Plitman E, Chung J, Iwata Y, Wilson A, Houle S, Menon M, Mamo D, Graff-Guerrero A. Lack of decrease in dopamine D3 receptor availability - [11C]-(+)-PHNO and [11C]-raclopride positron emission tomography study. *Journal of Cerebral Blood Flow & Metabolism*. 2015; 35: 1812-8.
20. Fujii K, Uchida H, Suzuki T, Mimura M. Dependence on benzodiazepines in patients with panic disorder: a cross-sectional study. *Psychiatry Clin Neurosci*. 2015; 69: 93-99.
21. Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Zakzanis KK, Graff-Guerrero A,

- Remington G. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. *Schizophrenia Research*. 2015; 161: 351-6.
22. Fervaha G, Agid O, Takeuchi H, Foussias G, Lee J, Remington G. Clinical and functional outcomes in people with schizophrenia with a high sense of well-being. *Journal of Nervous and Mental Disease*. 2015; 203: 187-93.
 23. Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Remington G. Relationship between symptomatic improvement and overall illness severity in patients with schizophrenia. *Journal of Clinical Psychopharmacology*. 2015; 35: 128-33.
 24. Caravaggio F, Raitsin S, Gerretsen P, Nakajima S, Wilson A, Graff-Guerrero A. Ventral Striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index. *Biol Psychiatry*. 2015; 77:196-202.
 25. Tada M, Uchida H, Mizushima J, Suzuki T, Mimura M, Nio S. Antidepressant dose and treatment response in bipolar depression: reanalysis of the systematic treatment enhancement program for bipolar disorder (STEP-BD) data. *J Psychiatr Res*. 2015; 68:151-56.
 26. Takeuchi H, Fervaha G, Remington G. Effect of antipsychotic dosing regimen on neurocognition in schizophrenia. *Journal of Clinical Psychopharmacology*. 2015; 35: 728-30.
 27. Takeuchi H, Remington G. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction. *Evidence-Based Mental Health*. 2015; 18: 117.
 28. Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Remington G. Relationship between symptomatic improvement and overall illness severity in patients with schizophrenia. *Journal of Clinical Psychopharmacology*. 2015; 35: 128-33.
 29. Lee J, Fervaha G, Takeuchi H, Powell V, Remington G. Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia. *Journal of Clinical Psychopharmacology*. 2015; 35: 237-41.
 30. Fervaha G, Hill C, Agid O, Takeuchi H, Foussias G, Siddiqui I, Kern RS, Remington G. Examination of the validity of the brief neurocognitive assessment (BNA) for schizophrenia. *Schizophrenia Research*. 2015; 166: 304-9.
 31. Lee J, Takeuchi H, Fervaha G, Powell V, Bhaloo A, Bies R, Remington G. The effect of clozapine on hematological indices: A 1-year follow-up study. *Journal of Clinical Psychopharmacology*. 2015; 35: 510-6.
 32. Fervaha G, Foussias G, Takeuchi H, Agid O, Remington G. Measuring motivation in people with schizophrenia. *Schizophrenia Research*. 2015; 169: 423-6.

33. Remington G, Agid O, Foussias G, Fervaha G, Takeuchi H, Lee J, Hahn M. What does schizophrenia teach us about antipsychotics? *Can J Psychiatry*. 2015; 60: S14-8.
34. Tomioka H, Yamagata B, Kawasaki S, Pu S, Iwanami A, Hirano J, Nakagome K, Mimura M. A longitudinal functional neuroimaging study in medication-naïve depression after antidepressant treatment, *PLoS One*. 2015; 10: e0120828.
35. Boileau I, Nakajima S, Payer D. Imaging the D3 dopamine receptor across behavioral and drug addictions: positron emission tomography studies with [11C]-(+)-PHNO. *Eur Neuropsychopharmacol*. 2015; 25: 1410-20.
36. Caravaggio F, Hahn M, Nakajima S, Gerretsen P, Remington G, Graff-Guerrero A. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. *Med Hypotheses*. 2015; 85: 391-6.

2014

1. Ishida T, Katagiri T, Uchida H, Takeuchi H, Sakurai H, Watanabe K, Mimura M. Incidence of deep vein thrombosis in restrained psychiatric patients. *Psychosomatics*. 2014; 55: 69-75.
2. Tsuboi T, Uchida H, Suzuki T, Mimura M. Effectiveness of Saikokaryukotsuboreito (herbal medicine) for antipsychotic-induced sexual dysfunction in male patients with schizophrenia: A description of two cases. *Case Reports in Psychiatry Article ID 784671*, 2014.
3. Yoshida K, Bies RR, Suzuki T, Remington G, Pollock BG, Mizuno Y, Mimura M, Uchida H. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. *Schizophr Res*. 2014; 153: 184-188.
4. Tada M, Uchida H, Suzuki T, Abe T, Pollock BG, Mimura M. Baseline difference between patients' and clinicians' rated illness severity scores and subsequent outcomes in major depressive disorder: analysis of the STAR*D data. *J Clin Psychopharm*. 2014; 34: 297-302.
5. Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. *Int J Neuropsychopharm*. 2014; 17: 1083-1093.
6. Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies RR, Grönte D, Remington G. Impact of once vs. twice daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. *J Clin Psychiatry*. 2014; 75: 506-511.

7. Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H. Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and QTc interval in stable patients with schizophrenia. *J Clin Psychopharmacology*. 2014; 34: 517-520.
8. Matsuoka T, Kato Y, Taniguchi S, Ogawa M, Fujimoto H, Okamura A, Shibata K, Nakamura K, Uchida H, Nakaaki S, Koumi H, Mimura M, Fukui K, Narumoto J. Japanese versions of the Executive Interview (J-EXIT25) and the Executive Clock Drawing Task (J-CLOX) for older people. *Int Psychogeriatr*. 2014; 26:1387-1397.
9. Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H. Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia. *Psychiatry Res*. 2014; 218: 244-246.
10. Uchida H, Suzuki T, Graff-Guerrero A, Mulsant BH, Pollock BG, Arenovich T, Rajji TK, Mamo DC. Therapeutic window for striatal dopamine D2/3 receptor occupancy in older patients with schizophrenia: a pilot PET study. *Am J Geriatr Psychiatry*. 2014; 22: 1007-1016.
11. Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. *Schizophr Bull*. 2014; 40: 1385-1403.
12. Uchida H, Suzuki T. Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications. *J Clin Psychopharmacol*. 2014; 34: 728-735.
13. Suzuki T, Uchida H, Takeuchi H, Tsuboi T, Hirano J, Mimura M. A review on schizophrenia and relapse - A quest for user-friendly psychopharmacotherapy. *Human Psychopharmacology: Clinical and Experimental*. 2014; 29: 414-426.
14. Ishida T, Suzuki T, Watanabe K, Sakurai H, Mimura M, Uchida H. Prophylactic use of heparin for deep vein thrombosis in restrained psychiatric patients: a chart review. *Gen Hosp Psychiatry*. 2014; 36: 690-693.
15. Suzuki T, Uchida H. Successful withdrawal from antipsychotic treatment in elderly male inpatients with schizophrenia - Description of four cases and review of the literature. *Psychiatr Res*. 2014; 220: 152-157.
16. Tarumi R, Suzuki T, Tani H, Den R, Sawada N, Sakurai H, Tsumi-Ozawa C, Ohtani A, Mimura M, Uchida H. Timing of adjunctive therapy in the treatment of depression: a chart review. *Pharmacopsychiatry*. 2014; 47: 259-262.
17. Ikai S, Suzuki T, Uchida H, Saruta J, Tsukinoki K, Fujii Y, Mimura M. Effects of yoga therapy on resilience and stress levels in patients with

- schizophrenia-spectrum disorders. *J Altern Complement Med.* 2014; 20: 823-830.
18. Suzuki T. Antipsychotic medications for schizophrenia. *JAMA.* 2014; 312:1468-9.
 19. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials *Schizophr Bull.* 2014; 40:192-213.
 20. Correll CU, Olvet DM, Auther AM, Hauser M, Kishimoto T, Carrión RE, Snyder S, Cornblatt BA. The Bipolar Prodrome Symptom Interview and Scale-Pro prospective (BPSS-P): description and validation in a psychiatric sample and healthy controls. *Bipolar Disord.* 2014; 16:505-22.
 21. Kishimoto T, Nitta M, Mimura M, Kane JM, Correll CU. Long acting injectable vs. oral antipsychotics in schizophrenia: a systematic review and meta-analysis of cohort studies. *Nihon Shinkei Seishin Yakurigaku Zasshi.* 2014; 34:61-2.
 22. Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study. *European Neuropsychopharmacology.* 2014; 24: 1078-85.
 23. Lee J, Takeuchi H, Fervaha G, Bhaloo A, Powell V, Remington G. Relationship between clinical improvement and functional gains with clozapine in schizophrenia. *European Neuropsychopharmacology.* 2014; 24: 1622-9.
 24. Lee J, Takeuchi H, Remington G. Comparing dopamine D2 receptor occupancies for use in clinical practice - attractive proposition but fraught with pitfalls. *Journal of Clinical Psychopharmacology.* 2014; 34: 530-2.
 25. Shinagawa S, Nakajima S, Plitman E, Graff-Guerrero A, Mimura M, Nakayama K, Miller B. Psychosis in Frontotemporal Dementia. *J Alzheimers Dis.* 2014; 42:485-99.
 26. Caravaggio F, Nakajima S, Borlido C, Remington G, Gerretsen P, Wilson A, Houle S, Menon M, Mamo D, Graff-Guerrero A. Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [11C]-(+)-PHNO. *Neuropsychopharmacology.* 2014; 39:2769-76.
 27. Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty M, Kobylanski J, Chung J, Caravaggio F, Iwata Y, Remington G, Graff-Guerrero A. Glutamate-Mediated Excitotoxicity in Schizophrenia: A Review. *Eur Neuropsychopharmacol.* 2014; 24:1591-605.
 28. Gerretsen P, Remington G, Borlido C, Quilty L, Hassan S, Polsinelli G, Teo C, Mar W, Simon R, Menon M, Pothier DD, Nakajima S, Caravaggio F, Mamo DC, Rajji TK,

Mulsant BH, Deluca V, Ganguli R, Pollock BG, Graff-Guerrero A. The VAGUS Insight into Psychosis Scale - Self-Report & Clinician-Rated Versions. *Psychiatry Res.* 2014; 220:1084-9.

29. Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies RR, Grönte D, Remington G. Impact of once vs. twice daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. *J Clin Psychiatry.* 2014; 75:506-11
30. Takeuchi H, Suzuki T, Bies RR, Remington G, Watanabe K, Mimura M, Uchida H. Dose reduction of risperidone or olanzapine and estimated dopamine D2 receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. *J Clin Psychiatry.* 2014; 75: 1209-14.

2013

1. Tani H, Uchida H, Suzuki T, Fujii Y, Mimura M. Interventions to reduce antipsychotic polypharmacy: a systematic review. *Schizophr Res.* 2013; 14: 215-20.
2. Sakurai H, Bies RR, Stroup SE, Keefe RSE, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. *Schizophr Bull.* 2013; 39: 564-74.
3. Tanaka S, Nagase T, Suzuki T, Nomura K, Takeuchi H, Nakajima S, Uchida H, Yagi G, Watanabe K, Mimura M. Factor structure of the targeted inventory on problems in schizophrenia. *Clin Psychopharmacology and Neuroscience.* 2013; 11:18-23.
4. Suzuki T, Graff-Guerrero A, Uchida H, Remington G, Caravaggio F, Borlido C, Pollock BG, Mulsant B, Deluca V, Ismail Z, Mamo D. Dopamine D2/3 occupancy of ziprasidone across a day: a within-subject PET study. *Psychopharmacology.* 2013; 228: 43-51.
5. Takahashi T, Uchida H, John M, Hirano J, Watanabe K, Mimura M, Correll C, Kishimoto T. The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort. *Schizophr Res.* 2013; 147: 383-6.
6. Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K, Mimura M, Pollock BG, Uchida H. Estimated dopamine D2 Receptor occupancy and remission in schizophrenia: analysis of the CATIE data. *J Clin Psychopharm.* 2013; 33: 682-5. Kishimoto T, Watanabe K, Uchida H, Mimura M, Kane JM, Correll CU.
7. Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales. *Psychiatric Res.* 2013; 209:406-11.
8. Ikai S, Suzuki T, Uchida H, Mimura M, Fujii Y. Reintroduction of clozapine after

perforation of the large intestine - A case report and review of the literature. *Ann Pharmacother.* 2013;47: e31.

9. Yoshida K, Suzuki T, Uchida H, Mimura M. Absence of evidence that p.r.n. regimen confers benefit: A review of the studies. *Int Clinical Psychopharmacol.* 2013; 28: 228-37.
10. Kikuchi T, Suzuki T, Uchida H, Watanabe K, Mimura M. Association between antidepressant side effects and functional impairment in patients with major depressive disorders. *Psychiatry Res.* 2013; 210:127-33.
11. Tsuboi T, Bies RR, Suzuki T, Mamo DC, Pollock BG, Graff-Guerrero A, Mimura M, Uchida H. Hyperprolactinemia and estimated dopamine D2 receptor occupancy and in patients with schizophrenia: analysis of the CATIE data. *Prog Neuropsychopharmacol Biol Psychiatry.* 2013; 45:178-82.
12. Uchida T, Suzuki T, Sakurai H, Tsutsumi C, Den R, Mimura M, Uchida H. 10-year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review. *Int Clin Psychopharm.* 2013; 28: 261-6.
13. Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, Watanabe K, Mimura M, Uchida H. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. *Schizophr Bull.* 2013; 39: 993-8.
14. Sakurai H, Uchida H, Abe T, Nakajima S, Suzuki T, Pollock BG, Sato Y, Mimura M. Trajectories of individual symptoms in remitters versus non-remitters with depression. *J Affect Disord.* 2013; 151: 506-13.
15. Ikai S, Uchida H, Suzuki T, Tsunoda K, Mimura M, Fujii Y. Effects of yoga therapy on postural stability in schizophrenia: a single-blind randomized controlled trial. *J Psychiatr Res.* 2013; 47: 1744-50.
16. Hirano J, Watanabe K, Suzuki T, Uchida H, Den R, Kishimoto T, Nagasawa T, Tomita Y, Hara K, Ochi H, Kobayashi Y, Ishi M, Fujita A, Kanai Y, Goto M, Hayashi H, Inamura K, Ooshima F, Sumida M, Ozawa T, Sekigawa K, Nagaoka M, Yoshimura K, Konishi M, Inagaki A, Saito T, Motohashi N, Mimura M, Ookubo Y, Kato M. An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. *Neuropsychiatr Dis Treat.* 2013; 9: 1553-1564.
17. Koizumi T, Uchida H, Suzuki T, Sakurai H, Tsunoda K, Nishimoto M, Ishigaki T, Goto M, Mimura M. Oversight of constipation in inpatients with schizophrenia: a cross-sectional study. *Gen Hosp Psychiatry.* 2013; 35: 649-652.
18. Mizushima J, Sakurai H, Mizuno Y, Shinfuku M, Tani H, Yoshida K, Ozawa C,

- Serizawa A, Koide S, Kodashiro N, Minamisawa A, Mutsumoto E, Nagai N, Noda S, Tachino G, Takahashi T, Takeuchi H, Kikuchi T, Uchida H, Watanabe K, Kocha H, Mimura M. Melancholic and reactive depression: a reappraisal of old categories. *BMC Psychiatry*. 2013; 13: 311.
19. Takeuchi T, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, Mimura M, Uchida H. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data. *Schizophr Res*. 2013; 150:373-379.
 20. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. *Mol Psychiatry*. 2013; 18:53-66.
 21. Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, Correll CU. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. *Schizophr Bull*. 2013; 39:1230-41.
 22. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. *J Clin Epidemiol*. 2013; 66:S37-41.
 23. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. *World Psychiatry*. 2013; 12:216-26.
 24. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long Acting Injectable vs. Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-Analysis of Mirror-Image Studies. *J Clin Psychiatry*. 2013; 74:957-65.
 25. Stentebjerg-Olesen M, Jeppesen P, Pagsberg AK, Fink-Jensen A, Kapoor S, Chekuri R, Carbon M, Al-Jadiri A, Kishimoto T, Kane JM, Correll CU. Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics. *J Child Adolesc Psychopharmacol*. 2013; 23:665-75.
 26. Kubota K, Okazaki M, Dobashi A, Yamamoto M, Hashiguchi M, Horie A, Inagaki A, Kikuchi T, Mochizuki M. Temporal relationship between multipledrugs and multiple events in patient reports on adverse drug reactions: findings in a pilot study in Japan. *Pharmacoepidemiol Drug Saf*. 2013; 22:1134-7.

27. Takeuchi H, Remington G. A Systematic Review of Reported Cases Involving Psychotic Symptoms Worsened by Aripiprazole in Schizophrenia or Schizoaffective Disorder. *Psychopharmacology*. 2013; 228: 175-85, 2013.
28. Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Le Foll B, Mulsant B, Pollock B, Graff-Guerrero A. The potential role of dopamine D₃ receptor neurotransmission in cognition. *Eur Neuropsychopharmacol*. 2013; 23:799-813.
29. Kane JM, Kishimoto T, Correll CU. The Comparative Effectiveness of Long-Acting Injectable vs. Oral Antipsychotic Medications in the Prevention of Relapse: A Case Study in CER in Psychiatry *J Clin Epidemiol*. 2013; 66:S37-41.
30. Suzuki T, Uchida H, Watanabe K, Mimura M. In Michael S. Ritsner, eds. *Polypharmacy in Psychiatry Practice. Volume 2. Use of Polypharmacy in the "Real World"armacy in I Antipsychotic Polypharmacy. Chapter 6. Antipsychotic Polypharmacy in Schizophrenia. How to Counteract This Common Practice?* Springer. 2013; 81-108.

2012

1. Sawada N, Uchida H, Watanabe K, Kikuchi T, Suzuki T, Kashima H, Mimura M. How accurate are physicians in eliciting the truth from their patients?: a large-scale internet survey from patients' perspectives. *J Clin Psychiatry*. 2012; 73:311-7.
2. Zahinoor I, Wessels A, Uchida H, Ng W, Mamo D, Rajji T, Pollock B, Mulsant B, Bies R. Age effects on clozapine clearance: age impacts clozapine exposure in inpatients and outpatients with schizophrenia. *Am J Geriatr Psychiatry*. 2012; 20: 53-60.
3. Uchida H, Mamo DC, Pollock BG, Suzuki T, Tsunoda K, Watanabe K, Mimura M, Bies RR. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. *Ther Drug Monit*. 2012; 34: 182-7.
4. Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. *Schizophr Res*. 2012; 134: 219-25.
5. Suzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, Graff-Guerrero A, Mimura M, Mamo DC. Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. *Psychiatry Res*. 2012; 197:1-6.
6. Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H. Dopamine D₂ Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data. *Schizophr Bull*. 2012;

39:564-74.

7. Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG, Tsuboi T, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012; 37: 182-7.
8. Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, Mimura M. Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial. *J Neurol Sci*. 2012; 315: 137-40.
9. Ikai S, Remington G, Suzuki T, Takeuchi H, Tsuboi T, Den R, Hirano J, Tsunoda K, Nishimoto M, Watanabe K, Mimura M, Mamo DC, *Uchida H. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: Implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. *J Clin Psychiatry*. 2012; 73: 1147-1152.
10. Shinfuku M, Uchida H, Tsutsumi C, Suzuki T, Watanabe K, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Mimura M, Kapur S. How psychotropic polypharmacy in schizophrenia begins – a longitudinal perspective. *Pharmacopsychiatry*. 2012; 45:133-7.
11. Kikuchi T, Miller JM, Schneck N, Oquendo MA, Mann JJ, Parsey RV, Keilp JG. Neural responses to incongruency in a blocked-trial Stroop fMRI task in major depressive disorder. *J Affect Disord*. 2012; 143:241-7.
12. Kikuchi T, Suzuki T, Uchida H, Watanabe K, Mimura M. Coping strategies for antidepressant side effects: An Internet survey. *J Affect Disord*. 2012; 143:89-94.
13. Kishimoto T, De Hert M, Carlson HE, Manu P, Correll CU. Osteoporosis and fracture risk in people with schizophrenia. *Curr Opin Psychiatry*. 2012; 25:415-429.
14. Nio S, Suzuki T, Uchida H, Watanabe K, Mimura M. Deficit status in bipolar disorder: investigation on prevalence rate and description of seven cases. *J Affect Disord*. 2012;143:248-52.
15. Kato Y, Uchida H, Mimura M. Mental health and psychosocial support after the Great East Japan Earthquake. *Keio J Med*. 2012; 61:15-22.
16. Suzuki T. Discontinuing donepezil or starting memantine for Alzheimer's disease. *N Engl J Med*. 2012; 366:2227-8.
17. Shinfuku M, Uchida H, Tsutsumi C, Suzuki T, Watanabe K, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Mimura M, Kapur S. How psychotropic polypharmacy in schizophrenia begins – a longitudinal perspective. *Pharmacopsychiatry*. 2012; 45:133-7.
18. Tani H, Uchida H, Suzuki T, Shibuya Y, Shimanuki H, Watanabe K, Den R,

Nishimoto M, Hirano J, Takeuchi H, Nio S, Nakajima S, Kitahata R, Tsuboi T, Tsunoda K, Kikuchi T, Mimura M. Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey. *BMC Oral Health*. 2012; 12:32.

2011

1. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. *J Clin Psychopharmacol*. 2011; 31: 497-502.
2. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Predicting dopamine D receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. *J Clin Psychopharmacol*. 2011; 31: 318-25.
3. Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. *Schizophr Bull*. 2011; 37: 788-99.
4. Uchida H, Chow TW, Mamo DC, Kapur S, Mulsant BH, Houle S, Pollock BG, Graff-Guerrero A. Effects of aging on 5-HT(2A) R binding: a HRRT PET study with and without partial volume corrections. *Int J Geriatr Psychiatry*. 2011; 26: 1300-8.
5. Tsutsumi C, Uchida H, Suzuki T, Watanabe K, Takeuchi H, Nakajima S, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Kapur S. The evolution of antipsychotic switch and polypharmacy in natural practice—a longitudinal perspective. *Schizophr Res*. 2011; 130: 40-6.
6. Tsuboi T, Suzuki T, Uchida H. A tipping point in drug dosing in late-life schizophrenia. *Curr Psychiatry Rep*. 2011; 13: 225-33.
7. Takeuchi H, Suzuki T, Uchida H, Kikuchi T, Nakajima S, Manki H, Watanabe K, Kashima H. How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review. *J Psychiatr Res*. 2011; 45: 1083-8.
8. Suzuki T, Uchida H, Watanabe K, Kashima H. Factors associated with response to clozapine in schizophrenia: A review. *Psychopharmacol Bull*. 2011; 44: 32-60.
9. Suzuki T, Remington G, Uchida H, Rajji TK, Graff-Guerrero A, Mamo DC. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. *Drugs Aging*. 2011; 28: 961-80.
10. Suzuki T, Remington G, Mulsant BH, Rajji TK, Uchida H, Graff-Guerrero A, Mamo DC. Treatment resistant schizophrenia and response to antipsychotics: a review. *Schizophr Res*. 2011; 133: 54-62.

11. Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A, Mamo DC. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. *Br J Psychiatry*. 2011; 199: 275-80.
12. Suzuki T. Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. *Psychopharmacol Bull*. 2011; 44: 32-60.
13. Suzuki T. Maternal depression and child development after prenatal DHA supplementation. *JAMA*. 2011; 305: 359-60; author reply 60-1.
14. Shinfuku M, Uchida H, Tsutsumi C, Suzuki T, Watanabe K, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Mimura M, Kapur S. How Psychotropic Polypharmacy in Schizophrenia Begins: A Longitudinal Perspective. *Pharmacopsychiatry*. 2011; 45:133-7.
15. Shinfuku M, Nakajima S, Uchida H, Watanabe K, Kocha H, Kashima H. Pisa syndrome caused by an acetylcholinesterase inhibitor in a patient with dementia with Lewy bodies. *Psychiatry Clin Neurosci*. 2011; 65: 299.
16. Nakajima S, Uchida H, Suzuki T, Watanabe K, Hirano J, Yagihashi T, Takeuchi H, Abe T, Kashima H, Mimura M. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011; 35: 1983-9.
17. Minamisawa A, Suzuki T, Watanabe K, Imasaka Y, Kimura Y, Takeuchi H, Nakajima S, Kashima H, Uchida H. Patient's trust in their psychiatrist: a cross-sectional survey. *Eur Arch Psychiatry Clin Neurosci*. 2011; 261: 603-8.
18. Koreki A, Tsunoda K, Suzuki T, Hirano J, Watanabe K, Kashima H, Uchida H. Clinical and demographic characteristics associated with postural instability in patients with schizophrenia. *J Clin Psychopharmacol*. 2011; 31: 16-21.
19. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. *Mol Psychiatry*. 2011; 18:53-66.
20. Kikuchi T, Uchida H, Suzuki T, Watanabe K, Kashima H. Patients' attitudes toward side effects of antidepressants: an Internet survey. *Eur Arch Psychiatry Clin Neurosci*. 2011; 261: 103-9.
21. Kikuchi T, Suzuki T, Uchida H, Watanabe K, Kashima H. Subjective recognition of adverse events with antidepressant in people with depression: a prospective study. *J Affect Disord*. 2011; 135: 347-53.
22. Ishida T, Uchida H, Suzuki T, Nakajima S, Watanabe K, Kashima H. Plasma substance P level in patients with schizophrenia: a cross-sectional study. *Psychiatry*

Clin Neurosci. 2011; 65: 526-8.

23. Hori K, Konishi K, Watanabe K, Uchida H, Tsuboi T, Moriyasu M, Tominaga I, Hachisu M. Influence of anticholinergic activity in serum on clinical symptoms of Alzheimer's disease. *Neuropsychobiology*. 2011; 63: 147-53.
24. Hazra M, Uchida H, Sproule B, Remington G, Suzuki T, Mamo DC. Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. *Psychiatry Clin Neurosci*. 2011; 65:676-8.
25. Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T, Kane JM. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. *Schizophr Res*. 2011; 131: 58-62.
26. Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical relevance in the treatment of schizophrenia. *Clin Ther*. 2011; 33: B16-39.
27. Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. *Dialogues Clin Neurosci*. 2011; 13: 155-72.

2010

1. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. *CNS Drugs*. 2010; 24: 35-53.
2. Uchida H, Suzuki T, Takeuchi H, Mamo DC. Analysis of antipsychotic dose reduction. *Am J Psychiatry*. 2010; 167: 994; author reply -5.
3. Tsunoda K, Uchida H, Suzuki T, Watanabe K, Yamashita T, Kashima H. Effects of discontinuing benzodiazepine-derivative hypnotics on postural sway and cognitive functions in the elderly. *Int J Geriatr Psychiatry*. 2010; 25: 1259-65.
4. Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study. *Psychiatry Clin Neurosci*. 2010; 64: 104-6.
5. Suzuki T, Uchida H, Nakajima S. Depression severity and effect of antidepressant medications. *JAMA*. 2010; 303: 1597-8; author reply 9.
6. Suzuki T, Takeuchi H, Nakajima S, Nomura K, Uchida H, Yagi G, Watanabe K, Kashima H. Magnitude of rater differences in assessment scales for schizophrenia. *J Clin Psychopharmacol*. 2010; 30: 607-11.
7. Sproule BA, Lake J, Mamo DC, Uchida H, Mulsant BH. Are antipsychotic

- prescribing patterns different in older and younger adults?: a survey of 1357 psychiatric inpatients in Toronto. *Can J Psychiatry*. 2010; 55: 248-54.
8. Rajji TK, Uchida H, Ismail Z, Ng W, Mamo DC, Remington G, Pollock BG, Mulsant BH. Clozapine and global cognition in schizophrenia. *J Clin Psychopharmacol*. 2010; 30: 431-6.
 9. Nakajima S, Suzuki T, Watanabe K, Kashima H, Uchida H. Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. *Prog Neuropsychopharmacol Biol Psychiatry*. 2010; 34: 259-64.
 10. Leon C, Gerretsen P, Uchida H, Suzuki T, Rajji T, Mamo DC. Sensitivity to antipsychotic drugs in older adults. *Curr Psychiatry Rep*. 2010; 12: 28-33.
 11. Konishi K, Hori K, Uchida H, Watanabe K, Tominaga I, Kimura M, Hosoyamada M, Shibasaki T, Kataoka A, Hachisu M. Adverse effects of anticholinergic activity on cognitive functions in Alzheimer's disease. *Psychogeriatrics*. 2010; 10: 34-8.
 12. Correll C, Kishimoto T, Carlson H. Review: most antipsychotic drugs more than double the prolactin levels in children and adolescents. *Evid Based Ment Health*. 2010; 13: 54.
 13. Baharnoori M, Bartholomeusz C, Boucher AA, Buchy L, Chaddock C, Chiliza B, Focking M, Fornito A, Gallego JA, Hori H, Huf G, Jabbar GA, Kang SH, El Kissi Y, Merchan-Naranjo J, Modinos G, Abdel-Fadeel NA, Neubeck AK, Ng HP, Novak G, Owolabi OO, Prata DP, Rao NP, Rieicansky I, Smith DC, Souza RP, Thienel R, Trotman HD, Uchida H, Woodberry KA, O'Shea A, DeLisi LE. The 2nd Schizophrenia International Research Society Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions. *Schizophr Res*. 2010; 124: e1-62.

2009

1. Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, Confavreux C, Klemenhagen KC, Tanaka KF, Gingrich JA, Guo XE, Tecott LH, Mann JJ, Hen R, Horvath TL, Karsenty G. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. *Cell*. 2009; 138: 976-89.
2. Uchida H, Suzuki T, Watanabe K, Kashima H. Should adjunctive antipsychotic treatment be continued in remitted patients with depression? *Psychiatry Clin Neurosci*. 2009; 63: 126.
3. Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tsunoda K, Takeuchi H, Kikuchi T, Nakajima S, Nomura K, Tomita M, Watanabe K, Kashima H. Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan. *Psychiatry Clin Neurosci*. 2009; 63: 244-6.

4. Uchida H, Suzuki T, Mamo DC, Mulsant BH, Kikuchi T, Takeuchi H, Tomita M, Watanabe K, Yagi G, Kashima H. Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan. *J Anxiety Disord.* 2009; 23: 477-81.
5. Uchida H, Rajji TK, Mulsant BH, Kapur S, Pollock BG, Graff-Guerrero A, Menon M, Mamo DC. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. *J Clin Psychopharmacol.* 2009; 29: 571-5.
6. Uchida H, Pollock BG, Bies RR, Mamo DC. Predicting age-specific dosing of antipsychotics. *Clin Pharmacol Ther.* 2009; 86: 360-2.
7. Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. *J Clin Psychiatry.* 2009; 70: 397-405.
8. Uchida H, Mamo DC. Dosing of antipsychotics in schizophrenia across the life-spectrum. *Prog Neuropsychopharmacol Biol Psychiatry.* 2009; 33: 917-20.
9. Uchida H, Kapur S, Mulsant BH, Graff-Guerrero A, Pollock BG, Mamo DC. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. *Am J Geriatr Psychiatry.* 2009; 17:255-63.
10. Uchida H, Graff-Guerrero A, Mulsant BH, Pollock BG, Mamo DC. Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics. *Schizophr Res.* 2009; 109: 130-3.
11. Tanaka H, Ma J, Tanaka KF, Takao K, Komada M, Tanda K, Suzuki A, Ishibashi T, Baba H, Isa T, Shigemoto R, Ono K, Miyakawa T, Ikenaka K. Mice with altered myelin proteolipid protein gene expression display cognitive deficits accompanied by abnormal neuron-glia interactions and decreased conduction velocities. *J Neurosci.* 2009; 29: 8363-71.
12. Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H. Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study. *J Clin Psychopharmacol.* 2009; 29: 394-5.
13. Suzuki T, Uchida H, Takeuchi H, Nakajima S, Nomura K, Tanabe A, Yagi G, Watanabe K, Kashima H. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. *Hum Psychopharmacol.* 2009; 24: 628-38.
14. Sawada N, Uchida H, Suzuki T, Watanabe K, Kikuchi T, Handa T, Kashima H. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. *BMC Psychiatry.* 2009; 9: 38.
15. Sado M, Knapp M, Yamauchi K, Fujisawa D, So M, Nakagawa A, Kikuchi T, Ono Y.

- Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. *Aust N Z J Psychiatry*. 2009; 43: 539-47.
16. Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G, Sproule B, Pollock BG, Mulsant BH, Bies RR. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. *Ther Drug Monit*. 2009; 31: 360-6.
 17. Nakajima S, Uchida H, Suzuki T, Watanabe K, Kashima H. Selective serotonin reuptake inhibitor-induced spermatorrhea in 2 patients. *J Clin Psychiatry*. 2009; 70: 1192-3.
 18. Nakajima S, Suzuki T, Watanabe K, Kashima H, Uchida H. Accelerating response to antidepressant treatment in depression: A review and clinical suggestions. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009; 34:259-64.
 19. Nakajima S, Suzuki T, Uchida H, Watanabe K, Kashima H. Antipsychotic-induced paroxysmal perceptual alteration in a patient with bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009; 33: 160-1
 20. Nakajima S, Ishida T, Akaishi R, Takahata K, Kitahata R, Uchida H, Suzuki T, Takeuchi H, Nomura K, Nakagawa A, Watanabe K, Kashima H. Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: a chart review. *J ECT*. 2009; 25: 178-81.
 21. Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA. Milnacipran versus other antidepressive agents for depression. *Cochrane Database Syst Rev*. 2009; 3: CD006529.
 22. Nakagawa A, Grunebaum MF, Oquendo MA, Burke AK, Kashima H, Mann JJ. Clinical correlates of planned, more lethal suicide attempts in major depressive disorder. *J Affect Disord*. 2009; 112: 237-42.
 23. Deltheil T, Tanaka K, Reperant C, Hen R, David DJ, Gardier AM. Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice. *Int J Neuropsychopharmacol*. 2009; 12: 1-11.
 24. Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C. Escitalopram versus other antidepressive agents for depression. *Cochrane Database Syst Rev*. 2009; 15: CD006532.
 25. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C. Sertraline versus other antidepressive agents for depression. *Cochrane Database Syst Rev*. 2009; 14: CD006117.
 26. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R,

- Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. *Lancet*. 2009; 373: 746-58.
27. Chow TW, Mamo DC, Uchida H, Graff-Guerrero A, Houle S, Smith GS, Pollock BG, Mulsant BH. Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT_{2A}) receptors in older, healthy adults. *BMC Med Imaging*. 2009; 9: 12.
28. Barbui C, Cipriani A, Furukawa TA, Salanti G, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, Geddes JR. Making the best use of available evidence: the case of new generation antidepressants: a response to: are all antidepressants equal? *Evid Based Ment Health*. 2009; 12:101-4.

2008

1. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G. *Lrp5* controls bone formation by inhibiting serotonin synthesis in the duodenum. *Cell*. 2008; 135: 825-37.
2. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. *J Clin Psychiatry*. 2008; 69: 1404-15.
3. Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tanabe A, Inagaki A, Watanabe K, Yagi G, Tomita M. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. *Am J Geriatr Psychiatry*. 2008; 16: 584-93.
4. Uchida H, Mamo DC, Kapur S, Labelle A, Shammi C, Mannaert EJ, Mann SW, Remington G. Monthly administration of long-acting injectable risperidone and striatal dopamine D₂ receptor occupancy for the management of schizophrenia. *J Clin Psychiatry*. 2008; 69: 1281-6.
5. Toda T, Hayakawa I, Matsubayashi Y, Tanaka K, Ikenaka K, Lu QR, Kawasaki H. Termination of lesion-induced plasticity in the mouse barrel cortex in the absence of oligodendrocytes. *Mol Cell Neurosci*. 2008; 39: 40-9.
6. Tatsumi K, Takebayashi H, Manabe T, Tanaka KF, Makinodan M, Yamauchi T, Makinodan E, Matsuyoshi H, Okuda H, Ikenaka K, Wanaka A. Genetic fate mapping of *Olig2* progenitors in the injured adult cerebral cortex reveals preferential differentiation into astrocytes. *J Neurosci Res*. 2008; 86: 3494-502.

7. Takeuchi H, Suzuki T, Uchida H, Nakajima S, Nomura K, Kikuchi T, Manki H, Watanabe K, Kashima H. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. *J Clin Psychopharmacol.* 2008; 28: 540-3.
8. Suzuki T, Uchida H, Watanabe K, Nakajima S, Nomura K, Takeuchi H, Tanabe A, Yagi G, Kashima H. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. *Hum Psychopharmacol.* 2008; 23: 455-63.
9. Suzuki T, Uchida H, Watanabe K, Kashima H. A potentially aborted neuroleptic malignant syndrome following seclusion against uncontrollable water intoxication. *Psychopharmacol Bull.* 2008; 41: 164-70.
10. Suzuki T, Uchida H, Watanabe K, Kashima H. Treatment target in schizophrenia: a critical review and a clinical suggestion. *Psychopharmacol Bull.* 2008; 41(4): 80-102.
11. Suzuki T, Uchida H, Nomura K, Takeuchi H, Nakajima S, Tanabe A, Yagi G, Watanabe K, Kashima H. Novel rating scales for schizophrenia – Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). *Schizophr Res.* 2008; 106: 328-36.
12. Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA. Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis. *CNS Drugs.* 2008; 22: 587-602.
13. Nakagawa A, Grunebaum MF, Sullivan GM, Currier D, Ellis SP, Burke AK, Brent DA, Mann JJ, Oquendo MA. Comorbid anxiety in bipolar disorder: does it have an independent effect on suicidality? *Bipolar Disord.* 2008; 10: 530-8.
14. Masuda M, Tanaka KF, Kanzaki S, Wakabayashi K, Oishi N, Suzuki T, Ikenaka K, Ogawa K. GFAP aggregates in the cochlear nerve increase the noise vulnerability of sensory cells in the organ of Corti in the murine model of Alexander disease. *Neurosci Res.* 2008; 62: 15-24.
15. Mamo DC, Uchida H, Vitcu I, Barsoum P, Gendron A, Goldstein J, Kapur S. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. *J Clin Psychiatry.* 2008; 69: 81-6.
16. Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the

hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. *J Clin Psychiatry*. 2008; 69: 385-91.

17. Fujisawa D, Hashimoto N, Masamune-Koizumi Y, Otsuka K, Tateno M, Okugawa G, Nakagawa A, Sato R, Kikuchi T, Tonai E, Yoshida K, Mori T, Takahashi H, Sato S, Igimi H, Waseda Y, Ueno T, Morokuma I, Takahashi K, Sartorius N. Pathway to psychiatric care in Japan: A multicenter observational study. *Int J Ment Health Syst*. 2008; 2: 14.
18. Deltheil T, Guiard BP, Cerdan J, David DJ, Tanaka KF, Reperant C, Guilloux JP, Coudore F, Hen R, Gardier AM. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. *Neuropharmacology*. 2008; 55: 1006-14.
19. Cipriani A, Furukawa TA, Geddes JR, Malvini L, Signoretti A, McGuire H, Churchill R, Nakagawa A, Barbui C. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. *J Clin Psychiatry*. 2008; 69: 1732-42.

2007

1. Tanaka KF, Takebayashi H, Yamazaki Y, Ono K, Naruse M, Iwasato T, Itohara S, Kato H, Ikenaka K. Murine model of Alexander disease: analysis of GFAP aggregate formation and its pathological significance. *Glia*. 2007; 55: 617-31.
2. Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?—A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. *Psychopharmacology (Berl)*. 2007; 195: 285-95.
3. Suzuki T, Uchida H, Watanabe K, Kashima H. Treating a schizophrenic patient with severe tardive dystonia without antipsychotics. *Prog Neuropsychopharmacol Biol Psychiatry*. 2007; 31: 1141-2.
4. Suzuki T, Uchida H, Watanabe K, Kashima H. Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report. *J Clin Pharm Ther*. 2007; 32: 525-7.
5. Nakajima S, Uchida H, Suzuki T, Tomita M, Tsunoda K, Kitta M, Takeuchi H, Nomura K, Watanabe K, Kashima H. An open-label trial of discontinuing benzodiazepines in patients with chronic schizophrenia. *J Clin Psychopharmacol*. 2007; 27: 401-3.

6. Nakagawa A, Grunebaum MF, Ellis SP, Oquendo MA, Kashima H, Gibbons RD, Mann JJ. Association of suicide and antidepressant prescription rates in Japan, 1999-2003. *J Clin Psychiatry*. 2007; 68: 908-16.
7. Ma J, Tanaka KF, Yamada G, Ikenaka K. Induced expression of cathepsins and cystatin C in a murine model of demyelination. *Neurochem Res*. 2007; 32: 311-20.

2006

1. Uchida H, Suzuki T, Yamazawa R, Tomita M, Nemoto T, Kimura Y, Watanabe K, Imasaka Y, Kashima H. Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack: an ideal treatment option in terms of the adverse effect. *J Clin Psychopharmacol*. 2006; 26: 50-5.
2. Uchida H, Suzuki T, Watanabe K, Kashima H. Antipsychotics-induced hypersensitivity of visual perception. *Eur Psychiatry*. 2006; 21: 343-4.
3. Tanaka KF, Ochi N, Hayashi T, Ikeda E, Ikenaka K. Fluoro-Jade: new fluorescent marker of Rosenthal fibers. *Neurosci Lett*. 2006; 407: 127-30.
4. Nakagawa A, Sato T, Endo Y, Watanabe K, Kashima H, Grunebaum MF. Prospective study of falls in long-term inpatients with chronic psychotic disorders. *Schizophr Res*. 2006; 88: 283-5.
5. Ma J, Matsumoto M, Tanaka KF, Takebayashi H, Ikenaka K. An animal model for late onset chronic demyelination disease caused by failed terminal differentiation of oligodendrocytes. *Neuron Glia Biol*. 2006; 2: 81-91.

2005

1. Uchida H, Watanabe K, Suzuki T, Goto A, Kashima H. Two case reports of successful prevention of overdosing in borderline patients. *Psychiatry*. 2005; 68: 179-82.
2. Uchida H, Takeuchi H, Suzuki T, Nomura K, Watanabe K, Kashima H. Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder. *J Clin Psychopharmacol*. 2005; 25: 545-51.
3. Suzuki T, Uchida H, Takeuchi H, Nomura K, Tanabe A, Watanabe K, Yagi G, Kashima H. Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. *Psychopharmacology (Berl)*. 2005; 181: 566-75.
4. Kishimoto T, Watanabe K, Takeuchi H, Kikuchi T, Nakajima S, Shimada N, Yagi G, Kashima H. Bone mineral density measurement in female inpatients with schizophrenia. *Schizophr Res*. 2005; 77: 113-5.

2004

1. Suzuki T, Uchida H, Watanabe K, Yagi G, Kashima H. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2004; 28: 361-9.
2. Suzuki T, Uchida H, Tanaka KF, Nomura K, Takano H, Tanabe A, Watanabe K, Yagi G, Kashima H. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. *Int J Neuropsychopharmacol*. 2004; 7: 133-42.

2003

1. Uchida H, Suzuki T, Watanabe K, Yagi G, Kashima H. Antipsychotic-induced paroxysmal perceptual alteration. *Am J Psychiatry*. 2003; 160: 2243-4.
2. Uchida H, Suzuki T, Tanaka KF, Watanabe K, Yagi G, Kashima H. Recurrent episodes of perceptual alteration in patients treated with antipsychotic agents. *J Clin Psychopharmacol*. 2003; 23: 496-9.
3. Suzuki T, Uchida H, Tanaka KF, Tomita M, Tsunoda K, Nomura K, Takano H, Tanabe A, Watanabe K, Yagi G, Kashima H. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. *Int Clin Psychopharmacol*. 2003; 18: 323-9.

2002

1. Tanaka KF, Kashima H, Suzuki H, Ono K, Sawada M. Existence of functional beta1- and beta2-adrenergic receptors on microglia. *J Neurosci Res*. 2002; 70: 232-7.

2000

1. Tanaka KF, Shintani F, Fujii Y, Yagi G, Asai M. Serum interleukin-18 levels are elevated in schizophrenia. *Psychiatry Res*. 2000; 96: 75-80.
2. Fujino T, Hasegawa M, Shibata S, Kishimoto T, Imai S, Takano T. PCCX1, a novel DNA-binding protein with PHD finger and CXXC domain, is regulated by proteolysis. *Biochem Biophys Res Commun*. 2000; 271: 305-10